Zymeworks Inchares (NYSE:ZYME) Shorts Strengthened By 0.28% As Of Dec 8, 2018

Zymeworks Inchares (NYSE:ZYME) recorded an increase of 0.28% in short interest. FINRA published in December ZYME’s total 546,200 short interest. The 544,700 previous shares are up with 0.28%. With Average volume 63,500, ZYME’s former position will take 9 days to restore. Float short on Zymeworks Inchares is 2.84%.

ZYME is reaching $13.14 during the last trading session, after increased 0.08%.Zymeworks Inc. is uptrending after having risen 74.85% since December 8, 2017. ZYME has 117,323 volume or 1.53% up from normal. The stock outperformed the S&P500 by 59.23%.

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada.The company has $419.91 million market cap. The companyÂ’s lead product candidate include ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast, gastric, and ovarian cancers.Currently it has negative earnings. It is also developing ZW33, a bispecific anti-human epidermal growth factor receptor 2 antibody-drug conjugate that is in preclinical development stage for the treatment of breast and ovarian cancers.

For more Zymeworks Inc. (NYSE:ZYME) news announced briefly go to: Seekingalpha.com, Fool.ca, Fool.ca, Fool.ca or Businesswire.com. The titles are as follows: “IPO Preview: Zymeworks Inc. – Seeking Alpha” announced on April 26, 2017, “Sick of Cannabis Stocks? These 3 Biotech Stocks Offer Huge Growth Potential – The Motley Fool Canada” on August 26, 2018, “This Biotech Stock Has Surged Over 100% in 2018: Is it Still a Buy Today? – The Motley Fool Canada” with a publish date: May 01, 2018, “2 Growth Stocks for Young Investors to Hold Forever – The Motley Fool Canada” and the last “Zymeworks Announces Selection of ZW25 Abstract for Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting – Business Wire” with publication date: April 25, 2018.

Zymeworks Inc. (NYSE:ZYME) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.